Project cooperationUpdated on 9 April 2026
Portfolio Company Collaboration: 20/20 OptimEyes Technologies
About
20/20 OptimEyes Technologies is developing a pipeline of long-acting therapies that treat diseases of the eye, lungs, bladder, and more by delivering proven drugs directly to mucosal surfaces—safely, effectively, and with less frequent dosing. Our lead program is a once-weekly eye drop for glaucoma, with additional candidates in ophthalmology, oncology, and respiratory segments. We are open to exploring collaborations with any novel small molecule assets that could benefit from our mucosal drug delivery platform.
Stage
- Execution
Topic
- Biotech, Pharma and Cosmetics
Type
- Research
- Technical
Attached files
Organisation
Similar opportunities
Project cooperation
- Execution
- Biotech, Pharma and Cosmetics
- Coordinator looking for partners
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada
Partnership
Advancing Clinical-Grade Botanical Therapeutics for Endometriosis
Gianluigi Corsetti
CEO EndOK at EndOK
Rome, Italy
Project cooperation
€4.7M seed investment SAFE/Convertible
- Early
- Other
- Other
- Biotech, Pharma and Cosmetics
Isabelle M Gorrillot, PhD
Co-founder, CEO at HO2Rx
Doylestown, United States